Carbidopa/levodopa - Jiangsu HengRui Medicine
Alternative Names: HRG-2010; Levodopa/carbidopa - Jiangsu HengRui MedicineLatest Information Update: 01 Oct 2024
At a glance
- Originator Jiangsu Hengrui Medicine Co.
- Class Antiasthmatics; Antiparkinsonians; Aromatic amino acids; Catecholamines; Hydrazines; Small molecules
- Mechanism of Action Decarboxylase inhibitors; Dopamine receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Parkinson's disease
Most Recent Events
- 20 Sep 2024 Jiangsu HengRui Medicine plans a phase III trial for Parkinson's disease (In adults, In the elderly) in China (PO), in September 2024 (NCT06596876)
- 04 Mar 2024 Jiangsu HengRui Medicine completes phase-II clinical trials in Parkinson's disease in China (PO, Capsule) (CTR20231044) (NCT06614153)
- 16 May 2023 Phase-II clinical trials in Parkinson's disease in China (PO, Capsule) (CTR20231044) (NCT06614153)